Merck & (NYSE: MRK) recently received a number of ratings updates from brokerages and research firms:

  • 11/1/2017 – Merck & was downgraded by analysts at Jefferies Group LLC from a “hold” rating to an “underperform” rating.
  • 11/1/2017 – Merck & had its “hold” rating reaffirmed by analysts at Berenberg Bank.
  • 10/31/2017 – Merck & was upgraded by analysts at Jefferies Group LLC from an “underperform” rating to a “hold” rating. They now have a $48.00 price target on the stock, down previously from $54.41.
  • 10/30/2017 – Merck & was downgraded by analysts at Barclays PLC from an “overweight” rating to an “equal weight” rating. They now have a $62.00 price target on the stock, down previously from $72.00.
  • 10/30/2017 – Merck & was downgraded by analysts at SunTrust Banks, Inc. from a “buy” rating to a “hold” rating.
  • 10/30/2017 – Merck & was downgraded by analysts at Morgan Stanley from an “overweight” rating to an “equal weight” rating. They now have a $56.00 price target on the stock.
  • 10/30/2017 – Merck & had its price target lowered by analysts at UBS AG from $72.00 to $67.00. They now have a “buy” rating on the stock.
  • 10/30/2017 – Merck & was upgraded by analysts at Citigroup Inc. to a “buy” rating.
  • 10/30/2017 – Merck & had its price target lowered by analysts at Leerink Swann from $70.00 to $69.00. They now have a “market perform” rating on the stock.
  • 10/30/2017 – Merck & was given a new $68.00 price target on by analysts at BMO Capital Markets. They now have a “buy” rating on the stock.
  • 10/29/2017 – Merck & was given a new $70.00 price target on by analysts at J P Morgan Chase & Co. They now have a “buy” rating on the stock.
  • 10/23/2017 – Merck & had its price target raised by analysts at Leerink Swann from $69.00 to $70.00. They now have a “market perform” rating on the stock.
  • 10/20/2017 – Merck & had its “sell” rating reaffirmed by analysts at Jefferies Group LLC. They now have a $55.00 price target on the stock.
  • 10/18/2017 – Merck & was upgraded by analysts at Citigroup Inc. from a “neutral” rating to a “buy” rating. They now have a $72.00 price target on the stock.
  • 10/18/2017 – Merck & was given a new $70.00 price target on by analysts at BMO Capital Markets. They now have a “buy” rating on the stock.
  • 10/17/2017 – Merck & was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Merck has made significant progress with its pipeline and is working on bringing new products to the market. New products like Keytruda and Zepatier should continue to contribute meaningfully to sales. Keytruda is gaining strong momentum from new indication of first-line lung cancer. The Keytruda development program also significantly advanced in the first half with several key regulatory approvals. Meanwhile, Merck will continue to focus on cost-cutting initiatives to drive the bottom line. However, generic competition for several drugs and pricing pressure will continue to be overhangs on the top line. Rising competition in the immuno-oncology market is also a significant concern. Merck’s shares underperformed the industry this year so far. Estimates have declined slightly ahead of the company’s Q3 earnings release. Merck has a positive record of earnings surprises in the recent quarters.”
  • 10/12/2017 – Merck & had its “outperform” rating reaffirmed by analysts at BMO Capital Markets. They now have a $72.00 price target on the stock.
  • 10/11/2017 – Merck & was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Merck’s new products like Keytruda and Zepatier should continue to contribute meaningfully to the top line. However, generic competition for several drugs will continue to be overhangs on the top line. Competitive and pricing pressures are also hurting sales of drugs like Isentress and Remicade. The diabetes franchise is also seeing slow sales since the past few quarters. Rising competition in the immuno-oncology market is also a significant concern. Meanwhile, Merck has also had its share of pipeline and regulatory setbacks. It recently dropped development of two of its HCV programs as the HCV market is becoming extremely crowded. Merck’s shares underperformed the industry this year so far. Estimates have remained stable ahead of the company’s Q3 earnings release. Merck has a positive record of earnings surprises in the recent quarters.”
  • 10/11/2017 – Merck & was given a new $70.00 price target on by analysts at BMO Capital Markets. They now have a “buy” rating on the stock.
  • 9/8/2017 – Merck & had its “buy” rating reaffirmed by analysts at BMO Capital Markets. They now have a $72.00 price target on the stock.
  • 9/5/2017 – Merck & had its “outperform” rating reaffirmed by analysts at Credit Suisse Group. They now have a $74.00 price target on the stock, down previously from $75.00.

Merck & (NYSE:MRK) last released its quarterly earnings results on Friday, October 27th. The company reported $1.11 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.03 by $0.08. Merck & had a net margin of 11.60% and a return on equity of 26.82%. The business had revenue of $10.33 billion for the quarter, compared to analyst estimates of $10.54 billion. During the same period in the previous year, the company earned $1.07 earnings per share. The business’s revenue for the quarter was down 2.0% on a year-over-year basis.

Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.

Receive News & Ratings for Merck & Company Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Company Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.